OncoMatch/Clinical Trials/NCT05176665
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Is NCT05176665 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies EMB-01 for neoplasms.
Treatment: EMB-01 — This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroendocrine Tumor
Biomarker criteria
Required: MET amplification
cMET amplification in tumor sample
Required: MET overexpression
cMET overexpression in tumor sample
Required: EGFR overexpression
EGFR overexpression in tumor sample
Required: EGFR gene alteration
Other EGFR ... gene alteration in blood sample (circulating tumor DNA, ctDNA)
Required: MET gene alteration
Other ... cMET gene alteration in blood sample (circulating tumor DNA, ctDNA)
Excluded: HER2 (ERBB2) gene alteration known to confer resistance to EGFR and/or cMET inhibitors
documented gene alteration including but not limited to HER2 ... that is known to confer resistance to EGFR and/or cMET inhibitors
Excluded: KRAS gene alteration known to confer resistance to EGFR and/or cMET inhibitors
documented gene alteration including but not limited to ... KRAS ... that is known to confer resistance to EGFR and/or cMET inhibitors
Excluded: NRAS gene alteration known to confer resistance to EGFR and/or cMET inhibitors
documented gene alteration including but not limited to ... NRAS ... that is known to confer resistance to EGFR and/or cMET inhibitors
Excluded: BRAF gene alteration known to confer resistance to EGFR and/or cMET inhibitors
documented gene alteration including but not limited to ... BRAF ... that is known to confer resistance to EGFR and/or cMET inhibitors
Excluded: NTRK1 gene alteration known to confer resistance to EGFR and/or cMET inhibitors
documented gene alteration including but not limited to ... NTRK ... that is known to confer resistance to EGFR and/or cMET inhibitors
Excluded: NTRK2 gene alteration known to confer resistance to EGFR and/or cMET inhibitors
documented gene alteration including but not limited to ... NTRK ... that is known to confer resistance to EGFR and/or cMET inhibitors
Excluded: NTRK3 gene alteration known to confer resistance to EGFR and/or cMET inhibitors
documented gene alteration including but not limited to ... NTRK ... that is known to confer resistance to EGFR and/or cMET inhibitors
Excluded: ALK gene alteration known to confer resistance to EGFR and/or cMET inhibitors
documented gene alteration including but not limited to ... ALK ... that is known to confer resistance to EGFR and/or cMET inhibitors
Excluded: RET gene alteration known to confer resistance to EGFR and/or cMET inhibitors
documented gene alteration including but not limited to ... RET ... that is known to confer resistance to EGFR and/or cMET inhibitors
Excluded: ROS1 gene alteration known to confer resistance to EGFR and/or cMET inhibitors
documented gene alteration including but not limited to ... ROS1 ... that is known to confer resistance to EGFR and/or cMET inhibitors
Excluded: FGFR1 gene alteration known to confer resistance to EGFR and/or cMET inhibitors
documented gene alteration including but not limited to ... FGFR ... that is known to confer resistance to EGFR and/or cMET inhibitors
Excluded: FGFR2 gene alteration known to confer resistance to EGFR and/or cMET inhibitors
documented gene alteration including but not limited to ... FGFR ... that is known to confer resistance to EGFR and/or cMET inhibitors
Excluded: FGFR3 gene alteration known to confer resistance to EGFR and/or cMET inhibitors
documented gene alteration including but not limited to ... FGFR ... that is known to confer resistance to EGFR and/or cMET inhibitors
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care therapies
Have failed all standard of care therapies known to confer clinical benefit. Patients who is not tolerable on standard of care therapies, or no standard of care therapies available, or refused standard of care therapies are eligible.
Lab requirements
Blood counts
Kidney function
Liver function
Must have adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05176665 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard of care therapies.
Does this trial require MET?
Yes, MET amplification is a required biomarker for enrollment.
Does this trial require MET?
Yes, MET overexpression is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR overexpression is a required biomarker for enrollment.
Are patients with ERBB2 alterations eligible?
No. ERBB2 gene alteration known to confer resistance to EGFR and/or cMET inhibitors is an exclusion criterion.
Are patients with KRAS alterations eligible?
No. KRAS gene alteration known to confer resistance to EGFR and/or cMET inhibitors is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages